Skip to main content

Commentary: A nuclear winter is coming for biopharma

The life sciences sector in Massachusetts, which has been flying so high for so long, is about to experience a very hard landing thanks to the adoption of prescription-drug-price controls in the Inflation Reduction Act (IRA), writes a Pioneer Institute fellow.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.